GR3015916T3 - Low toxicity drug-lipid systems. - Google Patents

Low toxicity drug-lipid systems.

Info

Publication number
GR3015916T3
GR3015916T3 GR950401037T GR950401037T GR3015916T3 GR 3015916 T3 GR3015916 T3 GR 3015916T3 GR 950401037 T GR950401037 T GR 950401037T GR 950401037 T GR950401037 T GR 950401037T GR 3015916 T3 GR3015916 T3 GR 3015916T3
Authority
GR
Greece
Prior art keywords
lipid
compositions
hdlcs
drug
lipid complexes
Prior art date
Application number
GR950401037T
Other languages
English (en)
Inventor
Lawrence Boni
Pieter R Cullis
Anthony G Durning
Andrew S Janoff
John J Kearns
Robert Klimchak
Robert P Lenk
Thomas Madden
Joel Portnoff
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27361805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3015916(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of GR3015916T3 publication Critical patent/GR3015916T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B2227/00—Photographic printing apparatus
    • G03B2227/32—Projection printing apparatus, e.g. enlarging apparatus, copying camera
    • G03B2227/325—Microcapsule copiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Vehicle Step Arrangements And Article Storage (AREA)
  • Catalysts (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
GR950401037T 1987-03-05 1995-04-25 Low toxicity drug-lipid systems. GR3015916T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2215787A 1987-03-05 1987-03-05
US6990887A 1987-07-06 1987-07-06
US7930987A 1987-07-29 1987-07-29

Publications (1)

Publication Number Publication Date
GR3015916T3 true GR3015916T3 (en) 1995-07-31

Family

ID=27361805

Family Applications (1)

Application Number Title Priority Date Filing Date
GR950401037T GR3015916T3 (en) 1987-03-05 1995-04-25 Low toxicity drug-lipid systems.

Country Status (20)

Country Link
EP (1) EP0282405B2 (el)
KR (1) KR970002870B1 (el)
CN (1) CN1044093C (el)
AT (1) ATE118169T1 (el)
AU (1) AU622405B2 (el)
CA (1) CA1338701C (el)
DE (1) DE3852961T3 (el)
DK (1) DK176010B1 (el)
ES (1) ES2070131T5 (el)
FI (1) FI102724B1 (el)
GR (1) GR3015916T3 (el)
HK (1) HK1007495A1 (el)
IE (1) IE67152B1 (el)
IL (1) IL85607A (el)
LU (1) LU88684I2 (el)
NL (1) NL990004I1 (el)
NO (4) NO179995C (el)
NZ (1) NZ223660A (el)
PT (1) PT86913B (el)
WO (1) WO1988006443A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5830498A (en) * 1987-10-16 1998-11-03 Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
CA2050679C (en) * 1989-03-31 1998-09-22 Francis C. Szoka, Jr. Preparation of liposome and lipid complex compositions
US5188951A (en) * 1990-04-17 1993-02-23 The Liposome Company, Inc. Enzymatic synthesis of soluble phosphatides from phospholipids
DE4108903A1 (de) * 1990-08-06 1992-02-13 Nattermann A & Cie Pharmazeutisches produkt
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
US5534502A (en) * 1990-11-06 1996-07-09 Nippon Shinyaku Co. Ltd. Process for producing fat emulsion
WO1992007571A1 (fr) * 1990-11-06 1992-05-14 Nippon Shinyaku Co., Ltd. Procede de production d'une emulsion grasse
EP0599977A1 (en) * 1991-08-14 1994-06-08 SEQUUS PHARMACEUTICALS, INC. (a Delaware Corporation) Hiv-treatment method with low-toxicity amphotericin b
JPH08510748A (ja) * 1993-05-21 1996-11-12 ザ リポソーム カンパニー、インコーポレーテッド リポソームが誘発する生理的副作用の低減
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
WO2007067784A2 (en) * 2005-12-08 2007-06-14 Wyeth Liposomal compositions
KR101132626B1 (ko) * 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
AU2010359346B2 (en) 2010-08-20 2015-01-29 Dr. Reddy's Laboratories Sa Phospholipid depot
ES2640756T3 (es) 2010-10-22 2017-11-06 Dr. Reddy's Laboratories Sa. Uso de depósitos de fosfolipidos viscosos estables para tratar heridas
RU2678433C2 (ru) 2012-05-10 2019-01-29 Пейнреформ Лтд. Депо-составы гидрофобного активного ингредиента и способы их получения
WO2016205384A1 (en) 2015-06-15 2016-12-22 The University Of Washington Multiple drug lipid nanoparticle composition and related methods for extended drug levels in blood and lymph tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4436746A (en) * 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
IL78929A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration

Also Published As

Publication number Publication date
ES2070131T3 (es) 1995-06-01
NO1998012I1 (no) 1998-03-25
KR970002870B1 (ko) 1997-03-12
DK176010B1 (da) 2005-11-28
ES2070131T5 (es) 1998-10-01
NO944071D0 (no) 1994-10-26
DK98089D0 (da) 1989-03-01
DE3852961D1 (de) 1995-03-23
NO1998013I1 (no) 1998-03-25
NO884391L (no) 1988-11-24
CN1044093C (zh) 1999-07-14
EP0282405A3 (en) 1989-01-04
DE3852961T2 (de) 1995-07-06
EP0282405B1 (en) 1995-02-08
CA1338701C (en) 1996-11-12
DK98089A (da) 1989-03-01
NZ223660A (en) 1990-11-27
EP0282405A2 (en) 1988-09-14
AU622405B2 (en) 1992-04-09
IL85607A0 (en) 1988-08-31
FI102724B (fi) 1999-02-15
IE67152B1 (en) 1996-03-06
KR890700341A (ko) 1989-04-24
LU88684I2 (fr) 1996-04-29
NO180147C (no) 1997-02-26
HK1007495A1 (en) 1999-04-16
EP0282405B2 (en) 1998-07-22
NO180147B (no) 1996-11-18
PT86913B (pt) 1993-07-30
WO1988006443A1 (en) 1988-09-07
NO944071L (no) 1988-11-24
DE3852961T3 (de) 1998-12-24
FI102724B1 (fi) 1999-02-15
NO884391D0 (no) 1988-10-04
PT86913A (pt) 1989-03-30
NL990004I1 (nl) 1999-04-01
CN88101864A (zh) 1988-09-28
FI894161A0 (fi) 1989-09-04
ATE118169T1 (de) 1995-02-15
IE880600L (en) 1988-09-05
IL85607A (en) 1992-08-18
AU1799088A (en) 1988-09-26
NO179995B (no) 1996-10-21
NO179995C (no) 1997-01-29

Similar Documents

Publication Publication Date Title
IL85607A0 (en) Low toxicity drug-lipid systems
HU9302496D0 (en) Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
CA2121345A1 (en) Lipophilic Oligosaccharide Antibiotic Salt Compositions
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
AU617998B2 (en) Anticoccidial composition
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
MY101079A (en) Pharmaceutical formulation for the treatment of bacterial infections.
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
Olay et al. Experimental Staphylococcus aureus osteomyelitis treated with fosfomycin and cephazolin: Single and combined therapy.
Dellamonica et al. Evaluation of rifampicin combined with a synergic antibiotic in severe staphylococcal infection. Report of selection of resistant mutants in seven cases.
CA2080040A1 (en) Methods for preventing mycobacterial infections by administration of rifabutin
EP0281092A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi
CA2564377A1 (en) 6-o-substituted ketolides having antibacterial activity